PreprintCase ReportVersion 1Preserved in Portico This version is not peer-reviewed
Evaluation of Potential Predictive Biomarkers for Defining Brain Radiotherapy Efficacy in NSCLC Patients with Brain Metastases: A Case Report and Review of Literature
Version 1
: Received: 6 June 2023 / Approved: 7 June 2023 / Online: 7 June 2023 (10:37:52 CEST)
How to cite:
Luciano, A.; Liguori, L.; Polcaro, G.; Sabbatino, F.; Pepe, S. Evaluation of Potential Predictive Biomarkers for Defining Brain Radiotherapy Efficacy in NSCLC Patients with Brain Metastases: A Case Report and Review of Literature. Preprints2023, 2023060535. https://doi.org/10.20944/preprints202306.0535.v1
Luciano, A.; Liguori, L.; Polcaro, G.; Sabbatino, F.; Pepe, S. Evaluation of Potential Predictive Biomarkers for Defining Brain Radiotherapy Efficacy in NSCLC Patients with Brain Metastases: A Case Report and Review of Literature. Preprints 2023, 2023060535. https://doi.org/10.20944/preprints202306.0535.v1
Luciano, A.; Liguori, L.; Polcaro, G.; Sabbatino, F.; Pepe, S. Evaluation of Potential Predictive Biomarkers for Defining Brain Radiotherapy Efficacy in NSCLC Patients with Brain Metastases: A Case Report and Review of Literature. Preprints2023, 2023060535. https://doi.org/10.20944/preprints202306.0535.v1
APA Style
Luciano, A., Liguori, L., Polcaro, G., Sabbatino, F., & Pepe, S. (2023). Evaluation of Potential Predictive Biomarkers for Defining Brain Radiotherapy Efficacy in NSCLC Patients with Brain Metastases: A Case Report and Review of Literature. Preprints. https://doi.org/10.20944/preprints202306.0535.v1
Chicago/Turabian Style
Luciano, A., Francesco Sabbatino and Stefano Pepe. 2023 "Evaluation of Potential Predictive Biomarkers for Defining Brain Radiotherapy Efficacy in NSCLC Patients with Brain Metastases: A Case Report and Review of Literature" Preprints. https://doi.org/10.20944/preprints202306.0535.v1
Abstract
Non-small-cell lung cancer (NSCLC) is the second most common cancer worldwide, resulting in 1.8 million deaths/year. Most of the patients are diagnosed with a metastatic disease. Central Nervous System is one of the major metastatic sites. Brain metastases are associated with severe neurological symptoms, shorter survival and worst clinical outcomes. Brain radiotherapy and systemic oncological therapies are currently used for controlling both cancer progression and neurological symptoms. Brain radiotherapy includes stereotactic brain ablative radiotherapy (SBRT) or whole brain radiotherapy (WBRT). SBRT is applied for single or multiple (≤ 4) small lesions (< 3 cm), while WBRT represents the best treatment choice in case of multiple and large brain metastases. In both cases radiotherapy application can represent an overtreatment causing severe toxicities without achieving a significant clinical benefit. So far, some scores have been proposed to define the potential clinical benefits derived from brain radiotherapy. However, most of them are not well validated into clinical practice. In this article, by presenting a clinical case of a patient with advanced NSCLC carrying a BRAFV600E mutation and brain metastases, we review the variables as well as the potential applicable scores to be considered in order to predict clinical outcomes and benefits from brain radiotherapy in patients with NSCLC and brain metastases.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
